VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q38327565 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000156.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q38327565‏
024 ‎‡a 0000-0002-2002-4339‏ ‎‡2 orcid‏
024 ‎‡a 7404846664‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q38327565‏
100 0 ‎‡a راسيل إي. لويس‏ ‎‡9 ar‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Russell E. Lewis‏ ‎‡9 ast‏ ‎‡9 it‏ ‎‡9 sl‏ ‎‡9 es‏
400 0 ‎‡a Russell E. Lewis‏ ‎‡c American medical researcher‏ ‎‡9 en‏
400 0 ‎‡a Russell E. Lewis‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
400 0 ‎‡a Russell E Lewis‏ ‎‡c Amerikanong tagapagpananaliksik‏ ‎‡9 tl‏
670 ‎‡a Author's A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response‏
670 ‎‡a Author's A Prospective Multicentre Study of the Epidemiology and Outcomes of Bloodstream Infection in Cirrhotic Patients‏
670 ‎‡a Author's A risk prediction score for invasive mold disease in patients with hematological malignancies‏
670 ‎‡a Author's Activity of deferasirox in Mucorales: influences of species and exogenous iron‏
670 ‎‡a Author's Aggressive versus conservative initiation of antibiotics‏
670 ‎‡a Author's Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility‏
670 ‎‡a Author's Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia‏
670 ‎‡a Author's Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods‏
670 ‎‡a Author's Antifungal activity againstScedosporiumspecies and novel assays to assess antifungal pharmacodynamics against filamentous fungi‏
670 ‎‡a Author's Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection‏
670 ‎‡a Author's Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection‏
670 ‎‡a Author's Antifungal drug resistance of pathogenic fungi.‏
670 ‎‡a Author's Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus‏
670 ‎‡a Author's Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites.‏
670 ‎‡a Author's Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes.‏
670 ‎‡a Author's Aspergillus nidulans is frequently resistant to amphotericin B.‏
670 ‎‡a Author's Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.‏
670 ‎‡a Author's Azoles and antidepressants: a mini-review of the tolerability of co-administration.‏
670 ‎‡a Author's Bloodstream infections in patients with liver cirrhosis‏
670 ‎‡a Author's Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis‏
670 ‎‡a Author's Candida albicans Cas5, a regulator of cell wall integrity, is required for virulence in murine and toll mutant fly models.‏
670 ‎‡a Author's Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome‏
670 ‎‡a Author's Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy‏
670 ‎‡a Author's Candidemia in patients with hematologic malignancies in the era of new antifungal agents‏
670 ‎‡a Author's Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection‏
670 ‎‡a Author's Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation: a management challenge‏
670 ‎‡a Author's Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.‏
670 ‎‡a Author's Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae‏
670 ‎‡a Author's Caspofungin-non-susceptible Candida isolates in cancer patients‏
670 ‎‡a Author's Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies‏
670 ‎‡a Author's Caspofungin versus liposomal amphotericin B for empirical therapy‏
670 ‎‡a Author's Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients‏
670 ‎‡a Author's Challenges in designing animal studies to detect antagonism of polyene activity‏
670 ‎‡a Author's Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine‏
670 ‎‡a Author's Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.‏
670 ‎‡a Author's Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species‏
670 ‎‡a Author's Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study‏
670 ‎‡a Author's Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.‏
670 ‎‡a Author's Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus‏
670 ‎‡a Author's Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis‏
670 ‎‡a Author's Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis‏
670 ‎‡a Author's Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae‏
670 ‎‡a Author's Comparison of oral immediate-release‏
670 ‎‡a Author's Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection‏
670 ‎‡a Author's Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis‏
670 ‎‡a Author's Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies.‏
670 ‎‡a Author's Computerized tomographic pulmonary angiography discriminates invasive mould disease of the lung from lymphoma.‏
670 ‎‡a Author's Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae‏
670 ‎‡a Author's Culture medium composition affects the lethality of Cunninghamella bertholletiae in a fly model of mucormycosis‏
670 ‎‡a Author's Current concepts in antifungal pharmacology‏
670 ‎‡a Author's Cutaneous model of invasive aspergillosis.‏
670 ‎‡a Author's Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma‏
670 ‎‡a Author's Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis‏
670 ‎‡a Author's Detection of gliotoxin in experimental and human aspergillosis‏
670 ‎‡a Author's Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease‏
670 ‎‡a Author's Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis‏
670 ‎‡a Author's Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections‏
670 ‎‡a Author's Different recommendations for daptomycin dosing over time in patients with severe infections‏
670 ‎‡a Author's Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis‏
670 ‎‡a Author's Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species‏
670 ‎‡a Author's Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis‏
670 ‎‡a Author's Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment‏
670 ‎‡a Author's Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.‏
670 ‎‡a Author's Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.‏
670 ‎‡a Author's Effect of combination therapy containing a high dose carbapenem on mortality in patients with carbapenem-resistant klebsiella pneumoniae bloodstream infection‏
670 ‎‡a Author's Effects of Aspergillus fumigatus gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis‏
670 ‎‡a Author's Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study‏
670 ‎‡a Author's Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies‏
670 ‎‡a Author's Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis‏
670 ‎‡a Author's Enemy of the‏
670 ‎‡a Author's Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection.‏
670 ‎‡a Author's Epidemiology and outcomes of bloodstream infection in patients with cirrhosis‏
670 ‎‡a Author's Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study‏
670 ‎‡a Author's Epidemiology and treatment of mucormycosis‏
670 ‎‡a Author's Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study‏
670 ‎‡a Author's Ethics. Constructing ethical guidelines for biohistory‏
670 ‎‡a Author's Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology‏
670 ‎‡a Author's Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study‏
670 ‎‡a Author's Exploring the concordance of Aspergillus fumigatus pathogenicity in mice and Toll-deficient flies.‏
670 ‎‡a Author's Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study‏
670 ‎‡a Author's Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus‏
670 ‎‡a Author's Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.‏
670 ‎‡a Author's Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center‏
670 ‎‡a Author's Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases.‏
670 ‎‡a Author's Future directions in mucormycosis research‏
670 ‎‡a Author's Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans‏
670 ‎‡a Author's Genomewide screening for genes associated with gliotoxin resistance and sensitivity in Saccharomyces cerevisiae‏
670 ‎‡a Author's High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia‏
670 ‎‡a Author's High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial‏
670 ‎‡a Author's High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies‏
670 ‎‡a Author's How does antifungal pharmacology differ for mucormycosis versus aspergillosis?‏
670 ‎‡a Author's Hyperthermia sensitizes Rhizopus oryzae to posaconazole and itraconazole action through apoptosis.‏
670 ‎‡a Author's Immunocompromised hosts: immunopharmacology of modern antifungals.‏
670 ‎‡a Author's Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy‏
670 ‎‡a Author's Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis‏
670 ‎‡a Author's Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections‏
670 ‎‡a Author's In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.‏
670 ‎‡a Author's In vitro interactions among echinocandins against Aspergillus fumigatus: lack of concordance among methods‏
670 ‎‡a Author's In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods‏
670 ‎‡a Author's In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp‏
670 ‎‡a Author's In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin‏
670 ‎‡a Author's In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.‏
670 ‎‡a Author's In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.‏
670 ‎‡a Author's Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011‏
670 ‎‡a Author's Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin‏
670 ‎‡a Author's Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation‏
670 ‎‡a Author's Increased culture recovery of Zygomycetes under physiologic temperature conditions‏
670 ‎‡a Author's Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli‏
670 ‎‡a Author's Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis‏
670 ‎‡a Author's Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis.‏
670 ‎‡a Author's Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin‏
670 ‎‡a Author's Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates‏
670 ‎‡a Author's Interactions of liposome carriers with infectious fungal hyphae reveals the role of β-glucans‏
670 ‎‡a Author's Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis‏
670 ‎‡a Author's Invasive aspergillosis in glucocorticoid-treated patients.‏
670 ‎‡a Author's Invasive aspergillosis in patients with hematologic malignancies.‏
670 ‎‡a Author's Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009.‏
670 ‎‡a Author's Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy‏
670 ‎‡a Author's Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.‏
670 ‎‡a Author's Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy‏
670 ‎‡a Author's Lack of galactomannan reactivity in dematiaceous molds recovered from cancer patients with phaeohyphomycosis‏
670 ‎‡a Author's Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment‏
670 ‎‡a Author's Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole‏
670 ‎‡a Author's Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals.‏
670 ‎‡a Author's Managing drug interactions in the patient with aspergillosis‏
670 ‎‡a Author's Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro‏
670 ‎‡a Author's Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study‏
670 ‎‡a Author's Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species‏
670 ‎‡a Author's Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis‏
670 ‎‡a Author's Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents‏
670 ‎‡a Author's Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy‏
670 ‎‡a Author's Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences‏
670 ‎‡a Author's Pentamidine is active in vitro against Fusarium species‏
670 ‎‡a Author's Phaeohyphomycosis in a tertiary care cancer center‏
670 ‎‡a Author's Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis‏
670 ‎‡a Author's Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity‏
670 ‎‡a Author's Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.‏
670 ‎‡a Author's Pharmacology of Systemic Antifungal Agents‏
670 ‎‡a Author's Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-centre study‏
670 ‎‡a Author's Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections‏
670 ‎‡a Author's Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer‏
670 ‎‡a Author's Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice‏
670 ‎‡a Author's Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study‏
670 ‎‡a Author's Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections‏
670 ‎‡a Author's Pulmonary candidiasis in patients with cancer: an autopsy study‏
670 ‎‡a Author's Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis‏
670 ‎‡a Author's Radiologic findings of Fusarium pneumonia in neutropenic patients‏
670 ‎‡a Author's Random plasma concentrations of voriconazole decline over time‏
670 ‎‡a Author's Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer.‏
670 ‎‡a Author's Reply to "Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?".‏
670 ‎‡a Author's Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion‏
670 ‎‡a Author's Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study.‏
670 ‎‡a Author's Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis.‏
670 ‎‡a Author's Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization‏
670 ‎‡a Author's Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study‏
670 ‎‡a Author's Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study‏
670 ‎‡a Author's Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections‏
670 ‎‡a Author's Role of mini-host models in the study of medically important fungi.‏
670 ‎‡a Author's Routine use of a real-time polymerase chain reaction method for detection of bloodstream infections in neutropaenic patients‏
670 ‎‡a Author's Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature‏
670 ‎‡a Author's Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006.‏
670 ‎‡a Author's Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity‏
670 ‎‡a Author's Serum bactericidal titres for monitoring antimicrobial therapy: current status and potential role in the management of multidrug-resistant gram-negative infections‏
670 ‎‡a Author's Serum galactomannan diagnosis of breakthrough invasive fungal disease‏
670 ‎‡a Author's Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi‏
670 ‎‡a Author's Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae‏
670 ‎‡a Author's The activity of amphotericin B against Candida albicans is not directly associated with extracellular calcium concentration‏
670 ‎‡a Author's The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis‏
670 ‎‡a Author's The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida‏
670 ‎‡a Author's The role of extended infusion β-lactams in the treatment of bloodstream infections in patients with liver cirrhosis‏
670 ‎‡a Author's The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?‏
670 ‎‡a Author's Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options‏
670 ‎‡a Author's Toll-deficient Drosophila are resistant to infection by Pneumocystis spp.: additional evidence of specificity to mammalian hosts‏
670 ‎‡a Author's Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence‏
670 ‎‡a Author's Toward more effective antifungal therapy: the prospects of combination therapy.‏
670 ‎‡a Author's Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single centre study‏
670 ‎‡a Author's Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.‏
670 ‎‡a Author's Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians‏
670 ‎‡a Author's Treatment principles for the management of mold infections‏
670 ‎‡a Author's Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension‏
670 ‎‡a Author's Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster‏
670 ‎‡a Author's What is the "therapeutic range" for voriconazole?‏
670 ‎‡a Author's Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases‏
909 ‎‡a (orcid) 0000000220024339‏ ‎‡9 1‏
909 ‎‡a (scopus) 7404846664‏ ‎‡9 1‏
919 ‎‡a evaluationofamphotericinbandflucytosineincombinationagainstcandidaalbicansandcryptococcusneoformansusingtimekillmethodology‏ ‎‡A Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology‏ ‎‡9 1‏
919 ‎‡a epidemiologyofinvasivepulmonaryaspergillosisamongcovid19intubatedpatientsaprospectivestudy‏ ‎‡A Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study‏ ‎‡9 1‏
919 ‎‡a epidemiologyandtreatmentofmucormycosis‏ ‎‡A Epidemiology and treatment of mucormycosis‏ ‎‡9 1‏
919 ‎‡a epidemiologyandsitesofinvolvementofinvasivefungalinfectionsinpatientswithhaematologicalmalignanciesa20yearautopsystudy‏ ‎‡A Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study‏ ‎‡9 1‏
919 ‎‡a epidemiologyandoutcomesofbloodstreaminfectioninpatientswithcirrhosis‏ ‎‡A Epidemiology and outcomes of bloodstream infection in patients with cirrhosis‏ ‎‡9 1‏
919 ‎‡a enemyoftheimmunosuppressedstateanupdateonthepathogenesisofaspergillusfumigatusinfection‏ ‎‡A Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection.‏ ‎‡9 1‏
919 ‎‡a enemyofthe‏ ‎‡A Enemy of the‏ ‎‡9 1‏
919 ‎‡a efficacyofcaspofungininneutropenicandcorticosteroidimmunosuppressedmurinemodelsofinvasivepulmonarymucormycosis‏ ‎‡A Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis‏ ‎‡9 1‏
919 ‎‡a efficacyandtoxicityofcaspofunginincombinationwithliposomalamphotericinbasprimaryorsalvagetreatmentofinvasiveaspergillosisinpatientswithhematologicmalignancies‏ ‎‡A Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies‏ ‎‡9 1‏
919 ‎‡a effectsofliposomalamphotericinbversusanamphotericinblipidcomplexonliverhistopathologyinpatientswithhematologicmalignanciesandinvasivefungalinfectionsaretrospectivenonrandomizedautopsystudy‏ ‎‡A Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study‏ ‎‡9 1‏
919 ‎‡a effectsofaspergillusfumigatusgliotoxinandmethylprednisoloneonhumanneutrophilsimplicationsforthepathogenesisofinvasiveaspergillosis‏ ‎‡A Effects of Aspergillus fumigatus gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis‏ ‎‡9 1‏
919 ‎‡a effectofcombinationtherapycontainingahighdosecarbapenemonmortalityinpatientswithcarbapenemresistantklebsiellapneumoniaebloodstreaminfection‏ ‎‡A Effect of combination therapy containing a high dose carbapenem on mortality in patients with carbapenem-resistant klebsiella pneumoniae bloodstream infection‏ ‎‡9 1‏
919 ‎‡a effectofamphotericinbandmicafungincombinationonsurvivalhistopathologyandfungalburdeninexperimentalaspergillosisinthep47phoxmousemodelofchronicgranulomatousdisease‏ ‎‡A Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.‏ ‎‡9 1‏
919 ‎‡a echinocandinresistanceincandidaspeciesmechanismsofreducedsusceptibilityandtherapeuticapproaches‏ ‎‡A Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.‏ ‎‡9 1‏
919 ‎‡a drosophilamelanogasterasamodeltoexploretheeffectsofmethicillinresistantstaphylococcusaureusstraintypeonvirulenceandresponsetolinezolidtreatment‏ ‎‡A Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment‏ ‎‡9 1‏
919 ‎‡a drosophilamelanogasterasamodelhosttodissecttheimmunopathogenesisofzygomycosis‏ ‎‡A Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis‏ ‎‡9 1‏
919 ‎‡a drosophilamelanogasterasafacilemodelforlargescalestudiesofvirulencemechanismsandantifungaldrugefficacyincandidaspecies‏ ‎‡A Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species‏ ‎‡9 1‏
919 ‎‡a doespreexposureofaspergillusfumigatustovoriconazoleorposaconazoleinvitroaffectitsvirulenceandtheinvivoactivityofsubsequentposaconazoleorvoriconazolerespectivelyastudyinaflymodelofaspergillosis‏ ‎‡A Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis‏ ‎‡9 1‏
919 ‎‡a differentrecommendationsfordaptomycindosingovertimeinpatientswithsevereinfections‏ ‎‡A Different recommendations for daptomycin dosing over time in patients with severe infections‏ ‎‡9 1‏
919 ‎‡a differencesintherateofcarbapenemresistantenterobacteriaceaecolonisationorclostridiumdifficileinfectionfollowingfrontlinetreatmentwithtigecyclinevsmeropenemforintraabdominalinfections‏ ‎‡A Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections‏ ‎‡9 1‏
919 ‎‡a developmentofaliganddirectedapproachtostudythepathogenesisofinvasiveaspergillosis‏ ‎‡A Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis‏ ‎‡9 1‏
919 ‎‡a developmentandapplicationsofprognosticriskmodelsinthemanagementofinvasivemolddisease‏ ‎‡A Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease‏ ‎‡9 1‏
919 ‎‡a detectionofgliotoxininexperimentalandhumanaspergillosis‏ ‎‡A Detection of gliotoxin in experimental and human aspergillosis‏ ‎‡9 1‏
919 ‎‡a delayingamphotericinbbasedfrontlinetherapysignificantlyincreasesmortalityamongpatientswithhematologicmalignancywhohavezygomycosis‏ ‎‡A Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis‏ ‎‡9 1‏
919 ‎‡a definingtheroleofechinocandincatecholfunctionalgroupsinthedevelopmentofsecondaryhepatocellularcarcinoma‏ ‎‡A Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma‏ ‎‡9 1‏
919 ‎‡a cutaneousmodelofinvasiveaspergillosis‏ ‎‡A Cutaneous model of invasive aspergillosis.‏ ‎‡9 1‏
919 ‎‡a currentconceptsinantifungalpharmacology‏ ‎‡A Current concepts in antifungal pharmacology‏ ‎‡9 1‏
919 ‎‡a culturemediumcompositionaffectsthelethalityofcunninghamellabertholletiaeinaflymodelofmucormycosis‏ ‎‡A Culture medium composition affects the lethality of Cunninghamella bertholletiae in a fly model of mucormycosis‏ ‎‡9 1‏
919 ‎‡a considerationsaboutantimicrobialstewardshipinsettingswithepidemicextendedspectrumβlactamaseproducingorcarbapenemresistantenterobacteriaceae‏ ‎‡A Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae‏ ‎‡9 1‏
919 ‎‡a computerizedtomographicpulmonaryangiographydiscriminatesinvasivemoulddiseaseofthelungfromlymphoma‏ ‎‡A Computerized tomographic pulmonary angiography discriminates invasive mould disease of the lung from lymphoma.‏ ‎‡9 1‏
919 ‎‡a computedtomographicpulmonaryangiographyfordiagnosisofinvasivemolddiseasesinpatientswithhematologicalmalignancies‏ ‎‡A Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies.‏ ‎‡9 1‏
919 ‎‡a comparisonofthedosedependentactivityandparadoxicaleffectofcaspofunginandmicafungininaneutropenicmurinemodelofinvasivepulmonaryaspergillosis‏ ‎‡A Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis‏ ‎‡9 1‏
919 ‎‡a comparisonoforalimmediatereleaseirandextendedreleaseermetronidazolebactericidalactivityagainstbacteroidessppusinganinvitromodelofinfection‏ ‎‡A Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection‏ ‎‡9 1‏
919 ‎‡a comparisonoforalimmediaterelease‏ ‎‡A Comparison of oral immediate-release‏ ‎‡9 1‏
919 ‎‡a comparativeserumbactericidalactivityofmeropenembasedcombinationregimensagainstextendedspectrumbetalactamaseandkpcproducingklebsiellapneumoniae‏ ‎‡A Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae‏ ‎‡9 1‏
919 ‎‡a comparativepharmacodynamicsofposaconazoleinneutropenicmurinemodelsofinvasivepulmonaryaspergillosisandmucormycosis‏ ‎‡A Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis‏ ‎‡9 1‏
919 ‎‡a comparativepharmacodynamicsofamphotericinblipidcomplexandliposomalamphotericinbinamurinemodelofpulmonarymucormycosis‏ ‎‡A Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis‏ ‎‡9 1‏
919 ‎‡a comparativeinvivodosedependentactivityofcaspofunginandanidulafunginagainstechinocandinsusceptibleandresistantaspergillusfumigatus‏ ‎‡A Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus‏ ‎‡9 1‏
919 ‎‡a comparativeanalysisofamphotericinblipidcomplexandliposomalamphotericinbkineticsoflungaccumulationandfungalclearanceinamurinemodelofacuteinvasivepulmonaryaspergillosis‏ ‎‡A Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.‏ ‎‡9 1‏
919 ‎‡a combinationofvoriconazoleandcaspofunginasprimarytherapyforinvasiveaspergillosisinsolidorgantransplantrecipientsaprospectivemulticenterobservationalstudy‏ ‎‡A Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study‏ ‎‡9 1‏
919 ‎‡a combinationofcaspofunginwithinhibitorsofthecalcineurinpathwayattenuatesgrowthinvitroinaspergillusspecies‏ ‎‡A Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species‏ ‎‡9 1‏
919 ‎‡a combinationchemotherapyforinvasivefungalinfectionswhatlaboratoryandclinicalstudiestellussofar‏ ‎‡A Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.‏ ‎‡9 1‏
919 ‎‡a combinationantifungaltherapyforbreakthroughinvasivemoulddiseaseinpatientswithhaematologicalmalignancieswhenmanagementreasoningeclipsesevidencebasedmedicine‏ ‎‡A Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine‏ ‎‡9 1‏
919 ‎‡a challengesindesigninganimalstudiestodetectantagonismofpolyeneactivity‏ ‎‡A Challenges in designing animal studies to detect antagonism of polyene activity‏ ‎‡9 1‏
919 ‎‡a ceftolozanetazobactamtreatmentofhypervirulentmultidrugresistant1pseudomonasaeruginosa1infectionsinneutropenicpatients‏ ‎‡A Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients‏ ‎‡9 1‏
919 ‎‡a caspofunginversusliposomalamphotericinbforempiricaltherapy‏ ‎‡A Caspofungin versus liposomal amphotericin B for empirical therapy‏ ‎‡9 1‏
919 ‎‡a caspofunginresistantcandidatropicalisstrainscausingbreakthroughfungemiainpatientsathighriskforhematologicmalignancies‏ ‎‡A Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies‏ ‎‡9 1‏
919 ‎‡a caspofunginnonsusceptiblecandidaisolatesincancerpatients‏ ‎‡A Caspofungin-non-susceptible Candida isolates in cancer patients‏ ‎‡9 1‏
919 ‎‡a caspofunginmediatedbetaglucanunmaskingandenhancementofhumanpolymorphonuclearneutrophilactivityagainstaspergillusandnonaspergillushyphae‏ ‎‡A Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae‏ ‎‡9 1‏
919 ‎‡a caspofunginasprimaryantifungalprophylaxisinstemcelltransplantrecipients‏ ‎‡A Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.‏ ‎‡9 1‏
919 ‎‡a carbapenemresistantklebsiellapneumoniaecolonizationatlivertransplantationamanagementchallenge‏ ‎‡A Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation: a management challenge‏ ‎‡9 1‏
919 ‎‡a candidemiainpatientswithhematologicmalignanciesintheeraofnewantifungalagents20012007stableincidencebutchangingepidemiologyofastillfrequentlylethalinfection‏ ‎‡A Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection‏ ‎‡9 1‏
919 ‎‡a candidemiainpatientswithhematologicmalignanciesintheeraofnewantifungalagents‏ ‎‡A Candidemia in patients with hematologic malignancies in the era of new antifungal agents‏ ‎‡9 1‏
919 ‎‡a candidemiainatertiarycarecancercenterinvitrosusceptibilityanditsassociationwithoutcomeofinitialantifungaltherapy‏ ‎‡A Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy‏ ‎‡9 1‏
919 ‎‡a candidalusitaniaefungemiaincancerpatientsriskfactorsforamphotericinbfailureandoutcome‏ ‎‡A Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome‏ ‎‡9 1‏
919 ‎‡a clinicopathologicalstudyofpulmonarymucormycosisincancerpatientsextensiveangioinvasionbutlimitedinflammatoryresponse‏ ‎‡A A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response‏ ‎‡9 1‏
919 ‎‡a candidaalbicanscas5aregulatorofcellwallintegrityisrequiredforvirulenceinmurineandtollmutantflymodels‏ ‎‡A Candida albicans Cas5, a regulator of cell wall integrity, is required for virulence in murine and toll mutant fly models.‏ ‎‡9 1‏
919 ‎‡a prospectivemulticentrestudyoftheepidemiologyandoutcomesofbloodstreaminfectionincirrhoticpatients‏ ‎‡A A Prospective Multicentre Study of the Epidemiology and Outcomes of Bloodstream Infection in Cirrhotic Patients‏ ‎‡9 1‏
919 ‎‡a riskpredictionscoreforinvasivemolddiseaseinpatientswithhematologicalmalignancies‏ ‎‡A A risk prediction score for invasive mold disease in patients with hematological malignancies‏ ‎‡9 1‏
919 ‎‡a activityofdeferasiroxinmucoralesinfluencesofspeciesandexogenousiron‏ ‎‡A Activity of deferasirox in Mucorales: influences of species and exogenous iron‏ ‎‡9 1‏
919 ‎‡a calcineurininhibitoragentsinteractsynergisticallywithantifungalagentsinvitroagainstcryptococcusneoformansisolatescorrelationwithoutcomeinsolidorgantransplantrecipientswithcryptococcosis‏ ‎‡A Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis‏ ‎‡9 1‏
919 ‎‡a bloodstreaminfectionsinpatientswithlivercirrhosis‏ ‎‡A Bloodstream infections in patients with liver cirrhosis‏ ‎‡9 1‏
919 ‎‡a azolesandantidepressantsaminireviewofthetolerabilityofcoadministration‏ ‎‡A Azoles and antidepressants: a mini-review of the tolerability of co-administration.‏ ‎‡9 1‏
919 ‎‡a aggressiveversusconservativeinitiationofantibiotics‏ ‎‡A Aggressive versus conservative initiation of antibiotics‏ ‎‡9 1‏
919 ‎‡a anidulafunginversuscaspofungininamousemodelofcandidiasiscausedbyanidulafunginsusceptiblecandidaparapsilosisisolateswithdifferentdegreesofcaspofunginsusceptibility‏ ‎‡A Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility‏ ‎‡9 1‏
919 ‎‡a attenuationoftheactivityofcaspofunginathighconcentrationsagainstcandidaalbicanspossibleroleofcellwallintegrityandcalcineurinpathways‏ ‎‡A Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.‏ ‎‡9 1‏
919 ‎‡a aspergillusnidulansisfrequentlyresistanttoamphotericinb‏ ‎‡A Aspergillus nidulans is frequently resistant to amphotericin B.‏ ‎‡9 1‏
919 ‎‡a aspergillusfumigatussuppressesthehumancellularimmuneresponseviagliotoxinmediatedapoptosisofmonocytes‏ ‎‡A Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes.‏ ‎‡9 1‏
919 ‎‡a aspergillusfumigatusinhibitsangiogenesisthroughtheproductionofgliotoxinandothersecondarymetabolites‏ ‎‡A Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites.‏ ‎‡9 1‏
919 ‎‡a aspergillosiscausedbynonfumigatusaspergillusspeciesriskfactorsandinvitrosusceptibilitycomparedwithaspergillusfumigatus‏ ‎‡A Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus‏ ‎‡9 1‏
919 ‎‡a antifungaldrugresistanceofpathogenicfungi‏ ‎‡A Antifungal drug resistance of pathogenic fungi.‏ ‎‡9 1‏
919 ‎‡a antifungalactivityofcolistinagainstmucoralesspeciesinvitroandinamurinemodelofrhizopusoryzaepulmonaryinfection‏ ‎‡A Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection‏ ‎‡9 1‏
919 ‎‡a antifungalactivityofamphotericinbfluconazoleandvoriconazoleinaninvitromodelofcandidacatheterrelatedbloodstreaminfection‏ ‎‡A Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection‏ ‎‡9 1‏
919 ‎‡a antifungalactivityagainstscedosporiumspeciesandnovelassaystoassessantifungalpharmacodynamicsagainstfilamentousfungi‏ ‎‡A Antifungal activity againstScedosporiumspecies and novel assays to assess antifungal pharmacodynamics against filamentous fungi‏ ‎‡9 1‏
919 ‎‡a antifungalactivitiesoffluconazolecaspofunginmk0991andanidulafunginly303366aloneandincombinationagainstcandidasppandcrytococcusneoformansviatimekillmethods‏ ‎‡A Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods‏ ‎‡9 1‏
919 ‎‡a antibacterialactivityoflinezolidandvancomycininaninvitropharmacodynamicmodelofgrampositivecatheterrelatedbacteraemia‏ ‎‡A Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia‏ ‎‡9 1‏
919 ‎‡a ethicsconstructingethicalguidelinesforbiohistory‏ ‎‡A Ethics. Constructing ethical guidelines for biohistory‏ ‎‡9 1‏
919 ‎‡a zygomycosisinatertiarycarecancercenterintheeraofaspergillusactiveantifungaltherapyacasecontrolobservationalstudyof27recentcases‏ ‎‡A Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases‏ ‎‡9 1‏
919 ‎‡a whatisthetherapeuticrangeforvoriconazole‏ ‎‡A What is the "therapeutic range" for voriconazole?‏ ‎‡9 1‏
919 ‎‡a virulencestudiesofscedosporiumandfusariumspeciesindrosophilamelanogaster‏ ‎‡A Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster‏ ‎‡9 1‏
919 ‎‡a usingstatetransitionmodelstoexplorehowtheprevalenceofsubtherapeuticposaconazoleexposuresimpactstheclinicalutilityoftherapeuticdrugmonitoringforposaconazoletabletsandoralsuspension‏ ‎‡A Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension‏ ‎‡9 1‏
919 ‎‡a treatmentprinciplesforthemanagementofmoldinfections‏ ‎‡A Treatment principles for the management of mold infections‏ ‎‡9 1‏
919 ‎‡a treatmentofmdrgramnegativeinfectionsinthe21stcenturyaneverendingthreatforclinicians‏ ‎‡A Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians‏ ‎‡9 1‏
919 ‎‡a treatmentofcarbapenemresistantklebsiellapneumoniaethestateoftheart‏ ‎‡A Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.‏ ‎‡9 1‏
919 ‎‡a treatmentdurationforescherichiacolibloodstreaminfectionandoutcomesretrospectivesinglecentrestudy‏ ‎‡A Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single centre study‏ ‎‡9 1‏
919 ‎‡a towardmoreeffectiveantifungaltherapytheprospectsofcombinationtherapy‏ ‎‡A Toward more effective antifungal therapy: the prospects of combination therapy.‏ ‎‡9 1‏
919 ‎‡a tolldeficientdrosophilafliesasafasthighthroughputmodelforthestudyofantifungaldrugefficacyagainstinvasiveaspergillosisandaspergillusvirulence‏ ‎‡A Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence‏ ‎‡9 1‏
919 ‎‡a tolldeficientdrosophilaareresistanttoinfectionbypneumocystissppadditionalevidenceofspecificitytomammalianhosts‏ ‎‡A Toll-deficient Drosophila are resistant to infection by Pneumocystis spp.: additional evidence of specificity to mammalian hosts‏ ‎‡9 1‏
919 ‎‡a therapyofcandidainfectionssusceptibilitytestingresistanceandtherapeuticoptions‏ ‎‡A Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options‏ ‎‡9 1‏
919 ‎‡a solubilityceilingarationaleforcontinuousinfusionamphotericinbtherapy‏ ‎‡A The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?‏ ‎‡9 1‏
919 ‎‡a roleofextendedinfusionβlactamsinthetreatmentofbloodstreaminfectionsinpatientswithlivercirrhosis‏ ‎‡A The role of extended infusion β-lactams in the treatment of bloodstream infections in patients with liver cirrhosis‏ ‎‡9 1‏
919 ‎‡a potentialimpactofantifungaldrugresistancemechanismsonthehostimmuneresponsetocandida‏ ‎‡A The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida‏ ‎‡9 1‏
919 ‎‡a impactofpriorinvasivemoldinfectionsinleukemiapatientswhoundergoallosctintheeraoftriazolebasedsecondaryprophylaxis‏ ‎‡A The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis‏ ‎‡9 1‏
919 ‎‡a activityofamphotericinbagainstcandidaalbicansisnotdirectlyassociatedwithextracellularcalciumconcentration‏ ‎‡A The activity of amphotericin B against Candida albicans is not directly associated with extracellular calcium concentration‏ ‎‡9 1‏
919 ‎‡a synergisticactivityofcolistinplusrifampinagainstcolistinresistantkpcproducingklebsiellapneumoniae‏ ‎‡A Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae‏ ‎‡9 1‏
919 ‎‡a stimulatedinnateresistanceoflungepitheliumprotectsmicebroadlyagainstbacteriaandfungi‏ ‎‡A Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi‏ ‎‡9 1‏
919 ‎‡a serumgalactomannandiagnosisofbreakthroughinvasivefungaldisease‏ ‎‡A Serum galactomannan diagnosis of breakthrough invasive fungal disease‏ ‎‡9 1‏
919 ‎‡a serumbactericidaltitresformonitoringantimicrobialtherapycurrentstatusandpotentialroleinthemanagementofmultidrugresistantgramnegativeinfections‏ ‎‡A Serum bactericidal titres for monitoring antimicrobial therapy: current status and potential role in the management of multidrug-resistant gram-negative infections‏ ‎‡9 1‏
919 ‎‡a sequentialexposureofaspergillusfumigatustoitraconazoleandcaspofunginevidenceofenhancedinvitroactivity‏ ‎‡A Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity‏ ‎‡9 1‏
919 ‎‡a scedosporiuminfectioninatertiarycarecancercenterareviewof25casesfrom1989‏ ‎‡A Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006.‏ ‎‡9 1‏
919 ‎‡a saprochaeteclavatainfectionsinpatientsundergoingtreatmentforhaematologicalmalignanciesareportofamonocentricoutbreakandreviewoftheliterature‏ ‎‡A Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature‏ ‎‡9 1‏
919 ‎‡a routineuseofarealtimepolymerasechainreactionmethodfordetectionofbloodstreaminfectionsinneutropaenicpatients‏ ‎‡A Routine use of a real-time polymerase chain reaction method for detection of bloodstream infections in neutropaenic patients‏ ‎‡9 1‏
919 ‎‡a roleofminihostmodelsinthestudyofmedicallyimportantfungi‏ ‎‡A Role of mini-host models in the study of medically important fungi.‏ ‎‡9 1‏
919 ‎‡a roleandinterpretationofantifungalsusceptibilitytestingforthemanagementofinvasivefungalinfections‏ ‎‡A Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections‏ ‎‡9 1‏
919 ‎‡a riskfactorsfortreatmentfailureinpatientsreceivingβlactamβlactamaseinhibitorcombinationsforenterobacteriaceaebloodstreaminfectionaretrospectivesinglecentrecohortstudy‏ ‎‡A Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study‏ ‎‡9 1‏
919 ‎‡a riskfactorsforrecurrentcarbapenemresistantklebsiellapneumoniaebloodstreaminfectionaprospectivecohortstudy‏ ‎‡A Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study‏ ‎‡9 1‏
919 ‎‡a riskfactorsforinfectionwithcarbapenemresistantklebsiellapneumoniaeafterlivertransplantationtheimportanceofpreandposttransplantcolonization‏ ‎‡A Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization‏ ‎‡9 1‏
919 ‎‡a riskfactorsforearlymortalityinhaematologicalmalignancypatientswithpulmonarymucormycosis‏ ‎‡A Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis.‏ ‎‡9 1‏
919 ‎‡a riskfactorsforcarbapenemresistantklebsiellapneumoniaebloodstreaminfectionamongrectalcarriersaprospectiveobservationalmulticentrestudy‏ ‎‡A Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study.‏ ‎‡9 1‏
919 ‎‡a reviewofinfluenzaassociatedpulmonaryaspergillosisinicupatientsandproposalforacasedefinitionanexpertopinion‏ ‎‡A Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion‏ ‎‡9 1‏
919 ‎‡a replytoriskforinvasivefungalinfectionsduringacutemyeloidleukemiainductiontherapyatrueassociationwithechinocandins‏ ‎‡A Reply to "Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?".‏ ‎‡9 1‏
919 ‎‡a rareopportunisticnoncandidanoncryptococcusyeastbloodstreaminfectionsinpatientswithcancer‏ ‎‡A Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer.‏ ‎‡9 1‏
919 ‎‡a randomplasmaconcentrationsofvoriconazoledeclineovertime‏ ‎‡A Random plasma concentrations of voriconazole decline over time‏ ‎‡9 1‏
919 ‎‡a radiologicfindingsoffusariumpneumoniainneutropenicpatients‏ ‎‡A Radiologic findings of Fusarium pneumonia in neutropenic patients‏ ‎‡9 1‏
919 ‎‡a quandariesofdecidingwhentochange1linetherapyininvasivepulmonaryaspergillosis‏ ‎‡A Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis‏ ‎‡9 1‏
919 ‎‡a pulmonarycandidiasisinpatientswithcanceranautopsystudy‏ ‎‡A Pulmonary candidiasis in patients with cancer: an autopsy study‏ ‎‡9 1‏
919 ‎‡a prognosticutilityofthenewdefinitionofdifficulttotreatresistanceamongpatientswithgramnegativebloodstreaminfections‏ ‎‡A Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections‏ ‎‡9 1‏
919 ‎‡a prognosticroleofbacterialandfungalinfectionsinpatientswithlivercirrhosiswithandwithoutacuteonchronicliverfailureaprospective2centerstudy‏ ‎‡A Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study‏ ‎‡9 1‏
919 ‎‡a pretreatmentwithemptyliposomesattenuatestheimmunopathologyofinvasivepulmonaryaspergillosisincorticosteroidimmunosuppressedmice‏ ‎‡A Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice‏ ‎‡9 1‏
919 ‎‡a predictorsofpulmonaryzygomycosisversusinvasivepulmonaryaspergillosisinpatientswithcancer‏ ‎‡A Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer‏ ‎‡9 1‏
919 ‎‡a predictorsofmortalityinmultidrugresistantklebsiellapneumoniaebloodstreaminfections‏ ‎‡A Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections‏ ‎‡9 1‏
919 ‎‡a potentialroleoft2candidainthemanagementofempiricalantifungaltreatmentinpatientsathighriskofcandidaemiaapilotsinglecentrestudy‏ ‎‡A Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-centre study‏ ‎‡9 1‏
919 ‎‡a pharmacologyofsystemicantifungalagents‏ ‎‡A Pharmacology of Systemic Antifungal Agents‏ ‎‡9 1‏
919 ‎‡a pharmacodynamicsofpolymyxinbagainstpseudomonasaeruginosa‏ ‎‡A Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.‏ ‎‡9 1‏
919 ‎‡a pharmacodynamicsofcaspofungininamurinemodelofinvasivepulmonaryaspergillosisevidenceofconcentrationdependentactivity‏ ‎‡A Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity‏ ‎‡9 1‏
919 ‎‡a pharmacodynamicactivityofamphotericinbdeoxycholateisassociatedwithpeakplasmaconcentrationsinaneutropenicmurinemodelofinvasivepulmonaryaspergillosis‏ ‎‡A Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis‏ ‎‡9 1‏
919 ‎‡a phaeohyphomycosisinatertiarycarecancercenter‏ ‎‡A Phaeohyphomycosis in a tertiary care cancer center‏ ‎‡9 1‏
919 ‎‡a pentamidineisactiveinvitroagainstfusariumspecies‏ ‎‡A Pentamidine is active in vitro against Fusarium species‏ ‎‡9 1‏
919 ‎‡a paradoxicaleffectofechinocandinsacrosscandidaspeciesinvitroevidenceforechinocandinspecificandcandidaspeciesrelateddifferences‏ ‎‡A Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences‏ ‎‡9 1‏
919 ‎‡a oralgentamicingutdecontaminationforpreventionofkpcproducingklebsiellapneumoniaeinfectionsrelevanceofconcomitantsystemicantibiotictherapy‏ ‎‡A Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy‏ ‎‡9 1‏
919 ‎‡a novelapproachtocharacterizationofcombinedpharmacodynamiceffectsofantimicrobialagents‏ ‎‡A Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents‏ ‎‡9 1‏
919 ‎‡a multidrugresistantendosymbioticbacteriaaccountfortheemergenceofzygomycosisahypothesis‏ ‎‡A Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis‏ ‎‡9 1‏
919 ‎‡a mucormycosiscausedbyunusualmucormycetesnonrhizopusmucorandlichtheimiaspecies‏ ‎‡A Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species‏ ‎‡9 1‏
919 ‎‡a monotherapywithcaspofunginforcandidaemiainadultpatientswithcanceraretrospectivesingleinstitutionstudy‏ ‎‡A Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study‏ ‎‡9 1‏
919 ‎‡a micafunginincombinationwithvoriconazoleinaspergillusspeciesapharmacodynamicapproachfordetectionofcombinedantifungalactivityinvitro‏ ‎‡A Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro‏ ‎‡9 1‏
919 ‎‡a managingdruginteractionsinthepatientwithaspergillosis‏ ‎‡A Managing drug interactions in the patient with aspergillosis‏ ‎‡9 1‏
919 ‎‡a macrophagereportercellassayforscreeningimmunopharmacologicalactivityofcellwallactiveantifungals‏ ‎‡A Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals.‏ ‎‡9 1‏
919 ‎‡a lovastatinhassignificantactivityagainstzygomycetesandinteractssynergisticallywithvoriconazole‏ ‎‡A Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole‏ ‎‡9 1‏
919 ‎‡a livertransplantationisassociatedwithgoodclinicaloutcomeinpatientswithactivetuberculosisandacuteliverfailureduetoantituberculartreatment‏ ‎‡A Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment‏ ‎‡9 1‏
919 ‎‡a lackofgalactomannanreactivityindematiaceousmoldsrecoveredfromcancerpatientswithphaeohyphomycosis‏ ‎‡A Lack of galactomannan reactivity in dematiaceous molds recovered from cancer patients with phaeohyphomycosis‏ ‎‡9 1‏
919 ‎‡a klebsiellapneumoniaebloodstreaminfectionepidemiologyandimpactofinappropriateempiricaltherapy‏ ‎‡A Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy‏ ‎‡9 1‏
919 ‎‡a itraconazolepreexposureattenuatestheefficacyofsubsequentamphotericinbtherapyinamurinemodelofacuteinvasivepulmonaryaspergillosis‏ ‎‡A Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.‏ ‎‡9 1‏
919 ‎‡a itraconazoleamphotericinbantagonisminaspergillusfumigatusanetestbasedstrategy‏ ‎‡A Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy‏ ‎‡9 1‏
919 ‎‡a invasivefusariosisinpatientswithhematologicmalignanciesatacancercenter1998‏ ‎‡A Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009.‏ ‎‡9 1‏
919 ‎‡a invasiveaspergillosisinpatientswithhematologicmalignancies‏ ‎‡A Invasive aspergillosis in patients with hematologic malignancies.‏ ‎‡9 1‏
919 ‎‡a invasiveaspergillosisinglucocorticoidtreatedpatients‏ ‎‡A Invasive aspergillosis in glucocorticoid-treated patients.‏ ‎‡9 1‏
919 ‎‡a interstrainvariabilityinthevirulenceofaspergillusfumigatusandaspergillusterreusinatolldeficientdrosophilaflymodelofinvasiveaspergillosis‏ ‎‡A Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis‏ ‎‡9 1‏
919 ‎‡a interactionsofliposomecarrierswithinfectiousfungalhyphaerevealstheroleofβglucans‏ ‎‡A Interactions of liposome carriers with infectious fungal hyphae reveals the role of β-glucans‏ ‎‡9 1‏
919 ‎‡a innateinflammatoryresponseandimmunopharmacologicactivityofmicafungincaspofunginandvoriconazoleagainstwildtypeandfksmutantcandidaglabrataisolates‏ ‎‡A Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates‏ ‎‡9 1‏
919 ‎‡a inhibitionofcandidaparapsilosismitochondrialrespiratorypathwaysenhancessusceptibilitytocaspofungin‏ ‎‡A Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin‏ ‎‡9 1‏
919 ‎‡a influenceofhostimmunosuppressiononctfindingsininvasivepulmonaryaspergillosis‏ ‎‡A Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis.‏ ‎‡9 1‏
919 ‎‡a increasedvirulenceofzygomycetesorganismsfollowingexposuretovoriconazoleastudyinvolvingflyandmurinemodelsofzygomycosis‏ ‎‡A Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis‏ ‎‡9 1‏
919 ‎‡a increasedfrequencyofnonfumigatusaspergillusspeciesinamphotericinbortriazolepreexposedcancerpatientswithpositiveculturesforaspergilli‏ ‎‡A Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli‏ ‎‡9 1‏
919 ‎‡a increasedculturerecoveryofzygomycetesunderphysiologictemperatureconditions‏ ‎‡A Increased culture recovery of Zygomycetes under physiologic temperature conditions‏ ‎‡9 1‏
919 ‎‡a increasedbonemarrowironstoresisanindependentriskfactorforinvasiveaspergillosisinpatientswithhighriskhematologicmalignanciesandrecipientsofallogeneichematopoieticstemcelltransplantation‏ ‎‡A Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation‏ ‎‡9 1‏
919 ‎‡a increasedbacterialadherenceandbiomassinpseudomonasaeruginosabacteriaexposedtoclarithromycin‏ ‎‡A Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin‏ ‎‡9 1‏
919 ‎‡a incidencedensityofinvasivefungalinfectionsduringprimaryantifungalprophylaxisinnewlydiagnosedacutemyeloidleukemiapatientsinatertiarycancercenter2009to‏ ‎‡A Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011‏ ‎‡9 1‏
919 ‎‡a invivoevolutionofresistantsubpopulationsofkpcproducingklebsiellapneumoniaeduringceftazidimeavibactamtreatment‏ ‎‡A In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.‏ ‎‡9 1‏
919 ‎‡a invivodynamicsofcarbapenemresistantpseudomonasaeruginosaselectionaftersuboptimaldosing‏ ‎‡A In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.‏ ‎‡9 1‏
919 ‎‡a invitropharmacodynamicsofrapidversuscontinuousinfusionofamphotericinbdeoxycholateagainstcandidaspeciesinthepresenceofhumanserumalbumin‏ ‎‡A In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin‏ ‎‡9 1‏
919 ‎‡a invitropharmacodynamicsofamphotericinbitraconazoleandvoriconazoleagainstaspergillusfusariumandscedosporiumspp‏ ‎‡A In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp‏ ‎‡9 1‏
919 ‎‡a invitropharmacodynamiccharacteristicsofflucytosinedeterminedbytimekillmethods‏ ‎‡A In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods‏ ‎‡9 1‏
919 ‎‡a invitrointeractionsamongechinocandinsagainstaspergillusfumigatuslackofconcordanceamongmethods‏ ‎‡A In vitro interactions among echinocandins against Aspergillus fumigatus: lack of concordance among methods‏ ‎‡9 1‏
919 ‎‡a invitroactivityandpostantibioticeffectsofcolistinincombinationwithotherantimicrobialsagainstcolistinresistantkpcproducingklebsiellapneumoniaebloodstreamisolates‏ ‎‡A In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.‏ ‎‡9 1‏
919 ‎‡a importanceofpharmacokineticconsiderationsforselectingtherapyinthetreatmentofinvasivefungalinfections‏ ‎‡A Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections‏ ‎‡9 1‏
919 ‎‡a implementationofameningitiscarebundleintheemergencyroomreducesmortalityassociatedwithacutebacterialmeningitis‏ ‎‡A Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis‏ ‎‡9 1‏
919 ‎‡a impactofahospitalwidemultifacetedprogrammeforreducingcarbapenemresistantenterobacteriaceaeinfectionsinalargeteachinghospitalinnorthernitaly‏ ‎‡A Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy‏ ‎‡9 1‏
919 ‎‡a immunocompromisedhostsimmunopharmacologyofmodernantifungals‏ ‎‡A Immunocompromised hosts: immunopharmacology of modern antifungals.‏ ‎‡9 1‏
919 ‎‡a hyperthermiasensitizesrhizopusoryzaetoposaconazoleanditraconazoleactionthroughapoptosis‏ ‎‡A Hyperthermia sensitizes Rhizopus oryzae to posaconazole and itraconazole action through apoptosis.‏ ‎‡9 1‏
919 ‎‡a howdoesantifungalpharmacologydifferformucormycosisversusaspergillosis‏ ‎‡A How does antifungal pharmacology differ for mucormycosis versus aspergillosis?‏ ‎‡9 1‏
919 ‎‡a highresolutioncomputedtomographyangiographyimprovestheradiographicdiagnosisofinvasivemolddiseaseinpatientswithhematologicalmalignancies‏ ‎‡A High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies‏ ‎‡9 1‏
919 ‎‡a highdoseweeklyliposomalamphotericinbantifungalprophylaxisinpatientsundergoinglivertransplantationaprospectivephase2trial‏ ‎‡A High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial‏ ‎‡9 1‏
919 ‎‡a highdoseinductionliposomalamphotericinbfollowedbydeescalationiseffectiveinexperimentalaspergillusterreuspneumonia‏ ‎‡A High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia‏ ‎‡9 1‏
919 ‎‡a genomewidescreeningforgenesassociatedwithgliotoxinresistanceandsensitivityinsaccharomycescerevisiae‏ ‎‡A Genomewide screening for genes associated with gliotoxin resistance and sensitivity in Saccharomyces cerevisiae‏ ‎‡9 1‏
919 ‎‡a genomewideexpressionprofilingrevealsgenesassociatedwithamphotericinbandfluconazoleresistanceinexperimentallyinducedantifungalresistantisolatesofcandidaalbicans‏ ‎‡A Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans‏ ‎‡9 1‏
919 ‎‡a futuredirectionsinmucormycosisresearch‏ ‎‡A Future directions in mucormycosis research‏ ‎‡9 1‏
919 ‎‡a fungalendophthalmitisinatertiarycarecancercenterareviewof23cases‏ ‎‡A Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases.‏ ‎‡9 1‏
919 ‎‡a frequencyandspeciesdistributionofgliotoxinproducingaspergillusisolatesrecoveredfrompatientsatatertiarycarecancercenter‏ ‎‡A Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center‏ ‎‡9 1‏
919 ‎‡a fitnessandvirulencecostsofcandidaalbicansfks1hotspotmutationsassociatedwithechinocandinresistance‏ ‎‡A Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.‏ ‎‡9 1‏
919 ‎‡a extracopiesoftheaspergillusfumigatussqualeneepoxidasegeneconferresistancetoterbinafinegeneticapproachtostudyinggenedosedependentresistancetoantifungalsinafumigatus‏ ‎‡A Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus‏ ‎‡9 1‏
919 ‎‡a extendedinfusionofβlactamsforbloodstreaminfectioninpatientswithlivercirrhosisanobservationalmulticenterstudy‏ ‎‡A Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study‏ ‎‡9 1‏
919 ‎‡a exploringtheconcordanceofaspergillusfumigatuspathogenicityinmiceandtolldeficientflies‏ ‎‡A Exploring the concordance of Aspergillus fumigatus pathogenicity in mice and Toll-deficient flies.‏ ‎‡9 1‏
919 ‎‡a evaluationofantifungalsinthesurgicalintensivecareunitamultiinstitutionalstudy‏ ‎‡A Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study‏ ‎‡9 1‏
943 ‎‡a 200x‏ ‎‡A 2006‏ ‎‡9 2‏
943 ‎‡a 201x‏ ‎‡A 2011‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 NII|DA0346046X‏
996 ‎‡2 ISNI|0000000024618332‏
996 ‎‡2 NII|DA00180263‏
996 ‎‡2 SUDOC|080303188‏
996 ‎‡2 CAOONL|ncf11304784‏
996 ‎‡2 LC|nr2004037970‏
996 ‎‡2 BIBSYS|90145929‏
996 ‎‡2 SUDOC|241442532‏
996 ‎‡2 BNF|12037320‏
996 ‎‡2 LC|nb2008016000‏
996 ‎‡2 ISNI|000000007573267X‏
996 ‎‡2 LC|no2018164789‏
996 ‎‡2 W2Z|1698988497409‏
996 ‎‡2 BIBSYS|90514460‏
996 ‎‡2 ISNI|0000000032350321‏
996 ‎‡2 SUDOC|200139428‏
996 ‎‡2 PLWABN|9810539962105606‏
996 ‎‡2 ISNI|0000000451334043‏
996 ‎‡2 ISNI|0000000499893952‏
996 ‎‡2 NTA|375541446‏
996 ‎‡2 J9U|987007384472105171‏
996 ‎‡2 NLA|000035035542‏
996 ‎‡2 LC|n 82244574‏
996 ‎‡2 RERO|A003518232‏
996 ‎‡2 BNF|12105974‏
996 ‎‡2 LC|no2001037000‏
996 ‎‡2 BAV|495_188680‏
996 ‎‡2 LC|nb2011005630‏
996 ‎‡2 ISNI|0000000053010668‏
996 ‎‡2 ISNI|000000039932893X‏
996 ‎‡2 DNB|170121461‏
996 ‎‡2 LC|no2009139168‏
996 ‎‡2 CAOONL|ncf10187148‏
996 ‎‡2 ISNI|0000000118101166‏
996 ‎‡2 BIBSYS|90136642‏
996 ‎‡2 NUKAT|n 97014391‏
996 ‎‡2 J9U|987007362386705171‏
996 ‎‡2 DBC|87097969576451‏
996 ‎‡2 NTA|069705356‏
996 ‎‡2 NTA|068205988‏
996 ‎‡2 LC|no2006057938‏
996 ‎‡2 LC|nr 95029805‏
996 ‎‡2 NKC|xx0176751‏
996 ‎‡2 PTBNP|118191‏
996 ‎‡2 LC|n 86830854‏
996 ‎‡2 ISNI|0000000039431503‏
996 ‎‡2 CAOONL|ncf12026839‏
996 ‎‡2 ISNI|0000000382122142‏
996 ‎‡2 RERO|A005974675‏
996 ‎‡2 CAOONL|ncf10732973‏
996 ‎‡2 VLACC|000042899‏
996 ‎‡2 ISNI|0000000102495375‏
996 ‎‡2 SUDOC|086003577‏
996 ‎‡2 DNB|1088335632‏
996 ‎‡2 LC|no2005012089‏
996 ‎‡2 BNF|12104778‏
996 ‎‡2 NII|DA05303032‏
996 ‎‡2 B2Q|0000065538‏
996 ‎‡2 LC|n 2012078883‏
996 ‎‡2 ISNI|0000000114738274‏
996 ‎‡2 ISNI|000000044736942X‏
996 ‎‡2 LC|n 2004004630‏
996 ‎‡2 SUDOC|031650244‏
996 ‎‡2 BIBSYS|1698988497409‏
996 ‎‡2 NTA|071567011‏
996 ‎‡2 BIBSYS|90168870‏
996 ‎‡2 BAV|495_128301‏
996 ‎‡2 NDL|00447605‏
996 ‎‡2 NTA|117322350‏
996 ‎‡2 CAOONL|ncf10242453‏
996 ‎‡2 ISNI|0000000040909906‏
996 ‎‡2 ISNI|0000000023401449‏
996 ‎‡2 LC|n 80106720‏
996 ‎‡2 ISNI|000000003648049X‏
996 ‎‡2 BIBSYS|90565036‏
996 ‎‡2 NUKAT|n 2017009229‏
996 ‎‡2 LC|no2023016448‏
996 ‎‡2 LC|no2015030830‏
996 ‎‡2 BNF|12282543‏
996 ‎‡2 RERO|A003518231‏
996 ‎‡2 RERO|A003518270‏
996 ‎‡2 NTA|303700815‏
996 ‎‡2 BIBSYS|14008311‏
996 ‎‡2 LC|nr2004010754‏
996 ‎‡2 LC|no 89000418‏
996 ‎‡2 BNF|14115810‏
996 ‎‡2 LC|no2010137494‏
996 ‎‡2 SUDOC|190546921‏
996 ‎‡2 J9U|987007316042705171‏
996 ‎‡2 LC|no2021129799‏
996 ‎‡2 SUDOC|094197652‏
996 ‎‡2 CAOONL|ncf10885029‏
996 ‎‡2 NKC|vse2017948911‏
996 ‎‡2 PLWABN|9813132839305606‏
996 ‎‡2 PLWABN|9810594681805606‏
996 ‎‡2 LC|n 50049595‏
996 ‎‡2 BIBSYS|90360347‏
996 ‎‡2 LC|nb2007025980‏
996 ‎‡2 J9U|987007319615605171‏
996 ‎‡2 LC|n 90679495‏
996 ‎‡2 SUDOC|083296832‏
996 ‎‡2 NTA|075259737‏
996 ‎‡2 LC|n 85823984‏
996 ‎‡2 ISNI|0000000437236412‏
996 ‎‡2 ISNI|0000000044393150‏
996 ‎‡2 BIBSYS|7066439‏
996 ‎‡2 BIBSYS|90072104‏
996 ‎‡2 ISNI|0000000001260526‏
996 ‎‡2 NII|DA08158949‏
996 ‎‡2 BIBSYS|12046794‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏